Rafael Amado - 01 Apr 2024 Form 4 Insider Report for Zai Lab Ltd (ZLAB)

Role
President, Head of Global Oncology Research and Development
Signature
/s/ Bruce Blefeld, Attorney-in-Fact
Issuer symbol
ZLAB
Transactions as of
01 Apr 2024
Net transactions value
$0
Form type
4
Filing time
03 Apr 2024, 21:43:50 UTC
Previous filing
19 Mar 2024
Next filing
05 Apr 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZLAB Stock Options (Right to Buy) Award $0 +120,141 $0.000000 120,141 01 Apr 2024 American Depositary Shares 120,141 $16.72 Direct F1, F2, F3
transaction ZLAB Restricted Share Units Award $0 +78,092 $0.000000 78,092 01 Apr 2024 American Depositary Shares 78,092 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Stock Option is exercisable for one American Depositary Share ("ADS"), which represents ten Ordinary Shares of the issuer.
F2 The option vests in equal annual installments over four years beginning on 04/01/2025, the first anniversary of the date of grant, subject to continuous service.
F3 Each ADS represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F4 Each Restricted Share Unit ("RSU") represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer.
F5 The RSUs vest in equal annual installments over four years beginning on 04/01/2025, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered to the reporting person following vesting.

Remarks:

President, Head of Global Oncology Research and Development